Is it practical to perform a study to manage antibiotic delivery in febrile neutropenia for children and young people undergoing treatment with anti-cancer drugs with the routine serial use of PCT measurements?
Not Applicable
Completed
- Conditions
- Febrile neutropenia in children and young people undergoing treatment for cancerCancer
- Registration Number
- ISRCTN13185152
- Lead Sponsor
- eeds Teaching Hospitals NHS Trust
- Brief Summary
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36053620/ (added 10/11/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Children aged birth to 18 years with cancer or cancer-like conditions* who are currently having systemic anticancer treatment and at risk of developing febrile neutropenia
Exclusion Criteria
Lack of informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recruitment rate recorded as the number of eligible participants who consent to participate in the study over 6 months
- Secondary Outcome Measures
Name Time Method <br> 1. Discontinuation adherence: proportion of episodes where antibiotics stopped according to PCT-guided recommendation over 6 months<br> 2. Safety: number potentially infection-related admissions to critical care after discontinuation of antibiotics over 6 months<br> 3. Recruitment strategy: proportion of potentially eligible patients who were approached to consent over 6 months<br> 4. Attrition: proportion of enrolled patients who then discontinued or declined intervention over 6 months<br> 5. Data quality: proportion of missing data on primary outcome measures over 6 months<br> 6. Impact on PCT on clinical decision making and reasons for adherence and non-adherence (qualitative data)<br> 7. Patient, parent and clinician attitudes to study (qualitative data) including the outcomes important to CYP/families<br>